Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018107100) MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/107100 International Application No.: PCT/US2017/065425
Publication Date: 14.06.2018 International Filing Date: 08.12.2017
IPC:
C07D 401/14 (2006.01) ,C07D 401/04 (2006.01) ,C07D 231/20 (2006.01) ,A61K 31/455 (2006.01) ,A61P 11/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
231
Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02
not condensed with other rings
10
having two or three double bonds between ring members or between ring members and non-ring members
14
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
18
One oxygen or sulfur atom
20
One oxygen atom attached in position 3 or 5
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
455
Nicotinic acid, i.e. niacin; Derivatives thereof, e.g. esters, amides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
Applicants:
VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 50 Northern Avenue Boston, MA 02210, US
Inventors:
ABELA, Alexander, Russell; US
ALCACIO, Timothy; US
ANDERSON, Corey; US
ANGELL, Paul, Timothy; US
BAEK, Minson; US
CLEMENS, Jeremy, J.; US
CLEVELAND, Thomas; US
FERRIS, Lori, Ann; US
GROOTENHUIS, Peter Diederik, Jan; US
GROSS, Raymond, Stanley; US
GULEVICH, Anton; US
HADIDA RUAH, Sara, Sabina; US
HSIA, Clara, Kuang-Ju; US
HUGHES, Robert, M.; US
JOSHI, Pramod, Virupax; US
KANG, Ping; US
KESHAVARZ-SHOKRI, Ali; US
KHATUYA, Haripada; US
KRENITSKY, Paul, John; US
MCCARTNEY, Jason; US
MILLER, Mark, Thomas; US
PARASELLI, Prasuna; US
PIERRE, Fabrice Jean, Denis; US
SHI, Yi; US
SHRESTHA, Muna; US
SIESEL, David, Andrew; US
STAVROPOULOS, Kathy; US
TERMIN, Andreas, P.; US
UY, Johnny; US
VAN GOOR, Fredrick, F.; US
YOUNG, Tomothy, John; US
ZHOU, Jinglan; US
Agent:
MACALPINE, Jill, K.; US
MACALPINE, Jill, K.; US
Priority Data:
62/432,53709.12.2016US
Title (EN) MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR
(FR) MODULATEUR DE RÉGULATEUR DE CONDUCTANCE TRANSMEMBRANAIRE DE FIBROSE KYSTIQUE, COMPOSITIONS PHARMACEUTIQUES, PROCÉDÉS DE TRAITEMENT ET PROCÉDÉ DE FABRICATION DU MODULATEUR
Abstract:
(EN) Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
(FR) L'invention concerne des composés de formule (I) des sels pharmaceutiquement acceptables de ceux-ci, des dérivés deutérés et des métabolites de l'un quelconque des précédents. L'invention concerne également des compositions pharmaceutiques comprenant les composés de l'invention, des procédés de traitement de la fibrose kystique à l'aide de celles-ci, et des procédés de fabrication de celles-ci. L'invention concerne en outre des formes à l'état solide du composé 1, des sels et des solvates de celui-ci.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)